2Seventy Bio Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Employees
-
65
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
2Seventy Bio General Information
Description
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Contact Information
Website
www.2seventybio.comCorporate Office
- 60 Binney Street
- Cambridge, MA 02142
- United States
Corporate Office
- 60 Binney Street
- Cambridge, MA 02142
- United States
2Seventy Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
2Seventy Bio Comparisons
Industry
Financing
Details
2Seventy Bio Competitors (10)
One of 2Seventy Bio’s 10 competitors is GT Biopharma, a Corporation company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GT Biopharma | Corporation | San Francisco, CA | ||||
| Cellectis | Formerly VC-backed | Paris, France | ||||
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Synthekine | Venture Capital-Backed | Menlo Park, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
2Seventy Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
2Seventy Bio Patents
2Seventy Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024229126-A2 | Mutant interleukin 15 expressing immune cells | Inactive | 01-May-2023 | ||
| WO-2024229126-A3 | Mutant interleukin 15 expressing immune cells | Inactive | 01-May-2023 | ||
| WO-2023230512-A1 | Compositions for maintaining lentiviral vector and uses thereof | Inactive | 26-May-2022 | ||
| WO-2023196996-A2 | Multipartite receptor and signaling complexes | Inactive | 08-Apr-2022 | ||
| WO-2023196996-A3 | Multipartite receptor and signaling complexes | Inactive | 08-Apr-2022 | A61K40/32 |
2Seventy Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
2Seventy Bio Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
2Seventy Bio FAQs
-
When was 2Seventy Bio founded?
2Seventy Bio was founded in 2021.
-
Where is 2Seventy Bio headquartered?
2Seventy Bio is headquartered in Cambridge, MA.
-
What is the size of 2Seventy Bio?
2Seventy Bio has 65 total employees.
-
What industry is 2Seventy Bio in?
2Seventy Bio’s primary industry is Drug Discovery.
-
Is 2Seventy Bio a private or public company?
2Seventy Bio is a Private company.
-
What is the current valuation of 2Seventy Bio?
The current valuation of 2Seventy Bio is .
-
What is 2Seventy Bio’s current revenue?
The current revenue for 2Seventy Bio is .
-
How much funding has 2Seventy Bio raised over time?
2Seventy Bio has raised $170M.
-
Who are 2Seventy Bio’s investors?
683 Capital Management, Armistice Capital, Bain Capital Life Sciences, Boxer Capital, and CaaS Capital Management are 5 of 14 investors who have invested in 2Seventy Bio.
-
Who are 2Seventy Bio’s competitors?
GT Biopharma, Cellectis, Mustang Bio, Synthekine, and Kite Pharma are some of the 10 competitors of 2Seventy Bio.
-
When was 2Seventy Bio acquired?
2Seventy Bio was acquired on 13-May-2025.
-
Who acquired 2Seventy Bio?
2Seventy Bio was acquired by Bristol-Myers Squibb.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
